"Cost Eff Resour Alloc"[Journal] - Search Results

Year	Number of Results
2003	8
2004	4
2005	11
2006	21
2007	16
2008	22
2009	20
2010	21
2011	18
2012	14
2013	31
2014	24
2015	23
2016	12
2017	22
2018	66
2019	29
2020	55
2021	81
2022	74
2023	97
2024	92
2025	96
2026	35

1

The evolution of cancer therapies and their Implications for health technology assessment in Australia.

Jones AM, Goodall S, Liew D, Kim H. Jones AM, et al. Cost Eff Resour Alloc. 2026 Mar 12. doi: 10.1186/s12962-026-00731-2. Online ahead of print. Cost Eff Resour Alloc. 2026. PMID: 41820975 Review. No abstract available.

2

The relative cost-effectiveness of atraumatic needles compared to conventional needles in diagnostic lumbar punctures.

Evans J, Lowin J, Anderson P. Evans J, et al. Cost Eff Resour Alloc. 2026 Mar 6. doi: 10.1186/s12962-025-00612-0. Online ahead of print. Cost Eff Resour Alloc. 2026. PMID: 41792808 Free article.

3

Associations between pharmaceutical industry interactions with physicians and chronic nonmalignant pain management prescribing practices: a systematic review.

Gharbia M, Iladiva L, Moriarty F, Fahey T, Larkin J. Gharbia M, et al. Cost Eff Resour Alloc. 2026 Mar 5;24(1):43. doi: 10.1186/s12962-026-00734-z. Cost Eff Resour Alloc. 2026. PMID: 41787406 Free PMC article. Review.

4

Cost-consequence analysis of a digital health-enabled non-communicable disease management intervention in Ghana.

Obeng AA, Bonney RA, Essel TYA, Wilberforce PAG, Agyei-Baffour P. Obeng AA, et al. Cost Eff Resour Alloc. 2026 Feb 27. doi: 10.1186/s12962-026-00733-0. Online ahead of print. Cost Eff Resour Alloc. 2026. PMID: 41749244 Free article. No abstract available.

5

Analysis of insecticide-treated bednet market dynamics between 2004-2021 and monetary value of additional bednet longevity.

McCoy A, Thomsen E, Spiers A, Worrall E. McCoy A, et al. Cost Eff Resour Alloc. 2026 Feb 25;24(1):41. doi: 10.1186/s12962-026-00725-0. Cost Eff Resour Alloc. 2026. PMID: 41736088 Free PMC article.

6

Epidemiological and economic impact of pre-exposure prophylaxis with targeted immunotherapies for COVID-19 among immunosuppressed patients in Argentina.

Moreno-López C, Rodríguez Cairoli F, Luxardo R, Augustovski F, Espinola N. Moreno-López C, et al. Cost Eff Resour Alloc. 2026 Feb 21. doi: 10.1186/s12962-026-00718-z. Online ahead of print. Cost Eff Resour Alloc. 2026. PMID: 41723474 Free article. No abstract available.

7

Economic evaluations of the primary prevention programs for viral hepatitis-related liver disease and liver cancer: a systematic literature review.

Lewandowska M, Cai S, Wijekulasuriya S, Dharmayani PNA, Carrigan A, Goodall S, Boutros R, George J, Zekry A, Zurynski Y. Lewandowska M, et al. Cost Eff Resour Alloc. 2026 Feb 19. doi: 10.1186/s12962-026-00727-y. Online ahead of print. Cost Eff Resour Alloc. 2026. PMID: 41715130 Free article. Review.

8

Willingness to pay for a quality-adjusted life year in Iran: a systematic review.

Hashempour R, AbolhasanBeigi Gallehzan N, Akhavan Rezayat S, Raei B, Esmaeili R, Emamgholipour Sefiddashti S. Hashempour R, et al. Cost Eff Resour Alloc. 2026 Feb 19. doi: 10.1186/s12962-026-00724-1. Online ahead of print. Cost Eff Resour Alloc. 2026. PMID: 41715116 Free article. Review. No abstract available.

9

Strategic resource allocation: an agent-based model of ambidextrous strategies in the pharmaceutical industry.

Pourzia S, Hajipour B. Pourzia S, et al. Cost Eff Resour Alloc. 2026 Feb 18. doi: 10.1186/s12962-026-00729-w. Online ahead of print. Cost Eff Resour Alloc. 2026. PMID: 41709224 Free article. No abstract available.

10

Comparison of national health planning policies in China and ASEAN: a PMC-index model analysis.

Feng J, Zhu C, Chen Y, Huang L, Huang Q, Qin Y, Wei J, Li Z, Feng Q, Qin X, Kang J. Feng J, et al. Cost Eff Resour Alloc. 2026 Feb 12. doi: 10.1186/s12962-026-00728-x. Online ahead of print. Cost Eff Resour Alloc. 2026. PMID: 41680890 Free article. No abstract available.

11

Battle against time for innovative cancer treatment: an updated cost-effectiveness analysis of pemigatinib in intrahepatic cholangiocarcinoma.

Wang IT, Chen HL, Huang WM, Chiang NJ, Shen LJ, Chueh CH, Tsai YW. Wang IT, et al. Cost Eff Resour Alloc. 2026 Feb 10. doi: 10.1186/s12962-025-00713-w. Online ahead of print. Cost Eff Resour Alloc. 2026. PMID: 41668195 Free article. No abstract available.

12

Benefit-cost analysis of nonprofit cataract surgery services in Latin America: a multinational evaluation through an SROI lens.

Lopez-Star E, Aleman-Castilla B, Ochoa Ramírez LA, Sánchez-Huerta V, Gómez Bastar PA, Portillo OG, Melgar MY, Guerrero RA, Cotrina FT, Dahik Loor AC. Lopez-Star E, et al. Cost Eff Resour Alloc. 2026 Feb 6;24(1):39. doi: 10.1186/s12962-026-00723-2. Cost Eff Resour Alloc. 2026. PMID: 41652475 Free PMC article.

13

Impact of hemodynamic management guided by intracranial compliance on the outcome of critically ill patients - preliminary results and exploratory economic evaluation.

Moreira CEN, Padovesi CM, Sales VVT, Holdack PJF, Furlan MMD, Tavares MS, Carnielo MT, Bianco AM. Moreira CEN, et al. Cost Eff Resour Alloc. 2026 Jan 30;24(1):38. doi: 10.1186/s12962-026-00721-4. Cost Eff Resour Alloc. 2026. PMID: 41618390 Free PMC article.

14

Cost-utility analysis of Edaravone compared to Riluzole in patients with amyotrophic lateral sclerosis (ALS) in Iran.

Omranikhoo H, Rezaee M, Verdizadeh A, Goudarzi Z, Jafari M, Gholami A, Poursadeghfard M, Keshavarz K. Omranikhoo H, et al. Cost Eff Resour Alloc. 2026 Jan 30. doi: 10.1186/s12962-025-00697-7. Online ahead of print. Cost Eff Resour Alloc. 2026. PMID: 41618386 Free article. No abstract available.

15

A decision-tree model to evaluate the impacts of workforce investments aimed at strengthening emergency obstetric and neonatal care (EmONC) facilities in Burundi.

Habonimana D, Leckcivilize A, Nicodemo C, Nzorironkankuze JB, Ndacayisaba A, Bishinga A, Ndayisenga J, Niane ESD, Bazikamwe S, Ndabashinze P, English M. Habonimana D, et al. Cost Eff Resour Alloc. 2026 Jan 29;24(1):37. doi: 10.1186/s12962-026-00720-5. Cost Eff Resour Alloc. 2026. PMID: 41612334 Free PMC article.

16

Complicated foot ulcers and high treatment costs in rural type 2 diabetic patients in vietnam: impact of infections on hospital stays.

Tung DD, Van Binh T, Lam NT, Long ND, Linh NP, Tuan TN, Xuan NT. Tung DD, et al. Cost Eff Resour Alloc. 2026 Jan 28;24(1):36. doi: 10.1186/s12962-026-00722-3. Cost Eff Resour Alloc. 2026. PMID: 41606664 Free PMC article.

17

Clinical and economic evaluation of risk factor guided respiratory syncytial virus prophylaxis in Colombian preterm infants.

Rodriguez-Martinez CE, Ordonez J, Carbonell-Estrany X, Fullarton J, Keary I, Rodgers-Gray B, D'Apremont I, Noyola DE, Ribeiro PA, Stein RT, Vain N, Tarride JE, Paes B. Rodriguez-Martinez CE, et al. Cost Eff Resour Alloc. 2026 Jan 27;24(1):35. doi: 10.1186/s12962-025-00710-z. Cost Eff Resour Alloc. 2026. PMID: 41593611 Free PMC article.

18

Does healthcare expenditure matter equally for all mental disorders? An international approach employing dynamic panel data methods.

Ortega-Perals P, Cruz Rambaud S, Sánchez García J. Ortega-Perals P, et al. Cost Eff Resour Alloc. 2026 Jan 24;24(1):33. doi: 10.1186/s12962-025-00706-9. Cost Eff Resour Alloc. 2026. PMID: 41580765 Free PMC article.

19

Use of resources and cost in the management of gastrointestinal hemorrhage caused by oral anticoagulants: a retrospective cohort analysis.

Machado-Duque ME, Gaviria-Mendoza A, Valladales-Restrepo LF, Gómez DM, Mesa-Urdinola A, Rubio AC, Reyes JM, Gamboa NC, Machado-Alba JE. Machado-Duque ME, et al. Cost Eff Resour Alloc. 2026 Jan 24;24(1):34. doi: 10.1186/s12962-025-00701-0. Cost Eff Resour Alloc. 2026. PMID: 41580730 Free PMC article.

20

Urban welfare and family-oriented settlement intentions of China's floating population.

Yang W, Zhu X, Xia Y. Yang W, et al. Cost Eff Resour Alloc. 2026 Jan 23;24(1):32. doi: 10.1186/s12962-026-00719-y. Cost Eff Resour Alloc. 2026. PMID: 41578356 Free PMC article.

21

Cost-effectiveness and return on investment of 20-valent pneumococcal conjugate vaccine use among adults in England: analysis from the societal perspective.

Mendes D, Averin A, Atwood M, Sato R, Vyse A, Campling J, Hariharan D, Weycker D, Mugwagwa T, Vietri J. Mendes D, et al. Cost Eff Resour Alloc. 2026 Jan 21;24(1):31. doi: 10.1186/s12962-025-00709-6. Cost Eff Resour Alloc. 2026. PMID: 41566327 Free PMC article.

22

Health technology assessment in Ghana: the development of the process guidelines using evidence-informed deliberative processes.

Surgey G, Asare BA, Baltussen R. Surgey G, et al. Cost Eff Resour Alloc. 2026 Jan 20;24(1):40. doi: 10.1186/s12962-025-00703-y. Cost Eff Resour Alloc. 2026. PMID: 41559782 Free PMC article.

23

A systematic review of data sources used for socioeconomic impact assessment of antimicrobial resistance from a One Health perspective: a lack of representative data.

Poonsiri C, Sukmanee J, Faradiba D, Chavarina KK, Prakash A, Anothaisintawee T, Chen YT, Sari EN, Xie Y, Pong CY, Lam ST, Lum E, Graves N, Wee HL, Teerawattananon Y. Poonsiri C, et al. Cost Eff Resour Alloc. 2026 Jan 18;24(1):30. doi: 10.1186/s12962-026-00715-2. Cost Eff Resour Alloc. 2026. PMID: 41549286 Free PMC article. Review.

24

Equity in health resource allocation in Guangdong Province, China, from 2013-2021: research based on the Dagum Gini coefficient and exploratory spatial data analysis.

Su W, Guan Z, Li X, Chen F, Guo P, Yuan C, Wang P. Su W, et al. Cost Eff Resour Alloc. 2026 Jan 17;24(1):29. doi: 10.1186/s12962-026-00714-3. Cost Eff Resour Alloc. 2026. PMID: 41547904 Free PMC article.

25

Cost-effectiveness of lenvatinib plus pembrolizumab as the second-line treatment for advanced endometrial carcinoma.

Chiang ST, Chueh CH, Wen YW, Chiang SC, Li WH, Tsai YW. Chiang ST, et al. Cost Eff Resour Alloc. 2026 Jan 14;24(1):42. doi: 10.1186/s12962-025-00711-y. Cost Eff Resour Alloc. 2026. PMID: 41535916 Free PMC article.

26

Cost-effectiveness of paramedic administered ketamine compared to morphine for the management of acute severe pain from traumatic injury.

Khan KA, Smyth M, Perkins GD, Yeung J, Walker A, McLaren R, Fuller G, Petrou S. Khan KA, et al. Cost Eff Resour Alloc. 2026 Jan 13;24(1):28. doi: 10.1186/s12962-025-00712-x. Cost Eff Resour Alloc. 2026. PMID: 41530853 Free PMC article.

27

Quantifying the direct costs of diabetic retinopathy in a mixed healthcare system: a hospital-based study from governmental and patient perspectives.

Jabbar RM, Al-Jumaili AA, Jaafar AD. Jabbar RM, et al. Cost Eff Resour Alloc. 2026 Jan 13;24(1):22. doi: 10.1186/s12962-026-00717-0. Cost Eff Resour Alloc. 2026. PMID: 41530807 Free PMC article.

28

Out-of-pocket expenditure in patients with isolated traumatic brain injury: a two center cohort study, a preliminary report.

Arora H, Patil S, Bhatia P, Khajanchi M, Sarang B, Nathani P, Dutta R, Khanna S, Bains L, Seit-Yagyayeva N, Patil P, Mishra A, Sawhney R, Mohan M, Kizhakke DV, Choubey U, Gadgil A, Roy N; IndSurg Collaborative. Arora H, et al. Cost Eff Resour Alloc. 2026 Jan 12;24(1):16. doi: 10.1186/s12962-026-00716-1. Cost Eff Resour Alloc. 2026. PMID: 41526931 Free PMC article.

29

A comparative health economic evaluation of venetoclax in combination with obinutuzumab versus Chlorambucil in combination with obinutuzumab as first-line treatment for chronic lymphocytic leukemia in China: a cost-effectiveness analysis.

Du J, Ran H, Zheng Z, Yu X, Feng T. Du J, et al. Cost Eff Resour Alloc. 2026 Jan 8;24(1):26. doi: 10.1186/s12962-025-00705-w. Cost Eff Resour Alloc. 2026. PMID: 41507978 Free PMC article.

30

Cost-utility analysis of free HPV immunization for girls in Rajasthan, India.

Munot S, Prasad N, Paudel R, Gaurav S, Saunik S, Paulino-Ramirez R, Ottoho E, Volquez M, Ripon R, Manghani P, Thakkar N, Gokhale S. Munot S, et al. Cost Eff Resour Alloc. 2026 Jan 7;24(1):25. doi: 10.1186/s12962-025-00708-7. Cost Eff Resour Alloc. 2026. PMID: 41501796 Free PMC article.

31

Health economics in Africa: historical perspectives, current challenges, and policy recommendations for sustainable healthcare financing and resource allocation.

Otorkpa OJ, Musa AU, Umar AP. Otorkpa OJ, et al. Cost Eff Resour Alloc. 2026 Jan 6;24(1):5. doi: 10.1186/s12962-025-00685-x. Cost Eff Resour Alloc. 2026. PMID: 41495801 Free PMC article. Review.

32

A digital diagnostic pathway for heart failure: an economic evaluation.

Mcmeekin N, Davies A, Petrie MC, Campbell RT, Lowe DJ, Murphy CL, Macklin L, Brooksbank K, Wu O. Mcmeekin N, et al. Cost Eff Resour Alloc. 2026 Jan 6;24(1):24. doi: 10.1186/s12962-025-00695-9. Cost Eff Resour Alloc. 2026. PMID: 41495745 Free PMC article.

33

Assessing the relationship between the hospital grading system and medical resource utilization: evidence from China.

Jia W, Wu X. Jia W, et al. Cost Eff Resour Alloc. 2026 Jan 5;24(1):2. doi: 10.1186/s12962-025-00672-2. Cost Eff Resour Alloc. 2026. PMID: 41486265 Free PMC article.

34

External fixation versus amputation in the treatment of ulcerated diabetic foot: a cost-utility analysis using real-world data and a discrete-event simulation model.

Roza Miguel PO, López Capdevila L, Rabanal Rubio M, Santamaría Fumas A, García-Rodríguez N, González Fidalgo E. Roza Miguel PO, et al. Cost Eff Resour Alloc. 2026 Jan 3;24(1):27. doi: 10.1186/s12962-025-00704-x. Cost Eff Resour Alloc. 2026. PMID: 41484873 Free PMC article.

35

External validation of the budget impact analysis of the drug fingolimode in the treatment of multiple sclerosis.

Campello CRS, da Costa MGS, Pinto M. Campello CRS, et al. Cost Eff Resour Alloc. 2026 Jan 2;24(1):23. doi: 10.1186/s12962-025-00698-6. Cost Eff Resour Alloc. 2026. PMID: 41484777 Free PMC article.

36

Community preferences for 'mental health insurance coverage in Tehran using a discrete choice experiment.

Talebianpour H, Daroudi R, Jaafaripooyan E, Sharafi E, Rahmani H. Talebianpour H, et al. Cost Eff Resour Alloc. 2025 Dec 30;24(1):21. doi: 10.1186/s12962-025-00687-9. Cost Eff Resour Alloc. 2025. PMID: 41469685 Free PMC article.

37

Economic evaluations of Glecaprevir/Pibrentasvir and Grazoprevir/Elbasvir for the treatment of hepatitis C: a systematic review.

Jafari M, Mehdizadeh P, Teymourzadeh E, Salesi M, Keshavarz K, Abyazi MA, Heiat M, Alavian SM. Jafari M, et al. Cost Eff Resour Alloc. 2025 Dec 29;24(1):20. doi: 10.1186/s12962-025-00700-1. Cost Eff Resour Alloc. 2025. PMID: 41462278 Free PMC article. Review.

38

The cost-utility analysis for the treatment of pediatric femoral shaft fracture.

Temtheerakij T, Angsanuntsukh C, Pattanaprateep O, Woratanarat T, Woratanarat P. Temtheerakij T, et al. Cost Eff Resour Alloc. 2025 Dec 29;23(1):75. doi: 10.1186/s12962-025-00680-2. Cost Eff Resour Alloc. 2025. PMID: 41462256 Free PMC article.

39

Cost-effectiveness of psychological treatment and support interventions for people living with HIV/AIDS: state of the evidence and policy considerations.

Kumah E, Boakye DS, Boateng R, Kokuro C, Ankomah SE, Fusheini A, Agyei E. Kumah E, et al. Cost Eff Resour Alloc. 2025 Dec 27;24(1):19. doi: 10.1186/s12962-025-00707-8. Cost Eff Resour Alloc. 2025. PMID: 41456044 Free PMC article.

40

An investigation of the quality of Syrian health insurance services via the SERVQUAL approach: a cross-sectional study.

Mouselli S, Allahham L, Al Ahdab S. Mouselli S, et al. Cost Eff Resour Alloc. 2025 Dec 27;24(1):17. doi: 10.1186/s12962-025-00691-z. Cost Eff Resour Alloc. 2025. PMID: 41455945 Free PMC article.

41

Disease-modifying treatments in paroxysmal nocturnal hemoglobinuria: a systematic review of economic evaluations.

Moradi S, Khajeamiri Y, Zandi S, Keramati M, Mohammadnezhad G. Moradi S, et al. Cost Eff Resour Alloc. 2025 Dec 27;24(1):18. doi: 10.1186/s12962-025-00702-z. Cost Eff Resour Alloc. 2025. PMID: 41455944 Free PMC article. Review.

42

Cost-effectiveness analysis of home-based palliative care for end-stage cancer patients.

Kubor P, Pourghaderi AR, Moeeni M, Rezayatmand R. Kubor P, et al. Cost Eff Resour Alloc. 2025 Dec 25;24(1):15. doi: 10.1186/s12962-025-00699-5. Cost Eff Resour Alloc. 2025. PMID: 41449462 Free PMC article.

43

Why will increasing medical insurance reimbursement levels not lead to over-medicalization? Evidence from China's medical insurance payment reform.

Yingtan M, Yaxuan Z, Qiuming H. Yingtan M, et al. Cost Eff Resour Alloc. 2025 Dec 23;24(1):14. doi: 10.1186/s12962-025-00689-7. Cost Eff Resour Alloc. 2025. PMID: 41437361 Free PMC article.

44

Cost-effectiveness of antihistaminics in adults' patients with allergic rhinitis.

Buendía JA, Patino DG. Buendía JA, et al. Cost Eff Resour Alloc. 2025 Dec 23;24(1):12. doi: 10.1186/s12962-025-00688-8. Cost Eff Resour Alloc. 2025. PMID: 41437259 Free PMC article.

45

Cost-effectiveness of short-term parent-infant-psychotherapy, results from two randomized controlled trials.

Kaß B, Berghöfer A, Kuchinke L, Ludwig-Koerner C, Schlensog-Schuster F, Roll S, Keil T, Reinhold T. Kaß B, et al. Cost Eff Resour Alloc. 2025 Dec 23;24(1):13. doi: 10.1186/s12962-025-00696-8. Cost Eff Resour Alloc. 2025. PMID: 41437254 Free PMC article.

46

Cost-effectiveness analysis of datopotamab deruxtecan versus docetaxel for previously treated advanced or metastatic non-small cell lung cancer.

Zeng F, Li S, Deng P. Zeng F, et al. Cost Eff Resour Alloc. 2025 Dec 22;23(1):77. doi: 10.1186/s12962-025-00694-w. Cost Eff Resour Alloc. 2025. PMID: 41430249 Free PMC article.

47

Cost-effectiveness analysis of different tracers (Patent Blue, Technetium-99 m, and Indocyanine Green) for Sentinel Lymph Node Biopsy procedure in breast cancer.

Denardi D, Oliveira-Junior I, Ferigatto JL, Buexm LA, Pereira AC, Vazquez FL. Denardi D, et al. Cost Eff Resour Alloc. 2025 Dec 18;24(1):11. doi: 10.1186/s12962-025-00693-x. Cost Eff Resour Alloc. 2025. PMID: 41413546 Free PMC article. Review.

48

Measurement, spatiotemporal evolution, and obstacle factor diagnosis of new quality productive forces in China's leading TCM manufacturing enterprises.

Zhiguang L, Yu Y, Jingyu S, Yushan C, Ruijin X. Zhiguang L, et al. Cost Eff Resour Alloc. 2025 Dec 17;24(1):10. doi: 10.1186/s12962-025-00692-y. Cost Eff Resour Alloc. 2025. PMID: 41408293 Free PMC article.

49

Economic evaluation of an employee health screening program for Hepatitis C virus in Pakistan.

Qureshi A, Bolas T, Khan UI, Malik AM, Risko N. Qureshi A, et al. Cost Eff Resour Alloc. 2025 Dec 17;24(1):9. doi: 10.1186/s12962-025-00683-z. Cost Eff Resour Alloc. 2025. PMID: 41402868 Free PMC article.

50

Reforming nursing reimbursement: direct payment models under Iran's Nursing Service Act in a global context.

Hatefimoadab N, Jaghargh MT, Abbaszadeh A, Sharafi S, Kianian T, Rezaiye M, Ebadi A. Hatefimoadab N, et al. Cost Eff Resour Alloc. 2025 Dec 12;24(1):8. doi: 10.1186/s12962-025-00690-0. Cost Eff Resour Alloc. 2025. PMID: 41388468 Free PMC article.

51

Early budget impact analysis of magnetic balloon technology for facilitating the completion of difficult colonoscopies.

Rognoni C, Cavallaro L, Repici A, Hassan C, Pellegatta G, Ciani O. Rognoni C, et al. Cost Eff Resour Alloc. 2025 Dec 12;23(1):73. doi: 10.1186/s12962-025-00676-y. Cost Eff Resour Alloc. 2025. PMID: 41388299 Free PMC article.

52

Associations of Alzheimer's disease with inpatient hospital costs and with quality-adjusted life years: evidence from conventional and Mendelian randomization analyses in the UK Biobank.

Dixon P, Anderson E. Dixon P, et al. Cost Eff Resour Alloc. 2025 Dec 10;24(1):7. doi: 10.1186/s12962-025-00684-y. Cost Eff Resour Alloc. 2025. PMID: 41366417 Free PMC article.

53

Drivers of sustainable procurement in the health sector: perspectives from key informant interviews of two teaching hospitals in Ghana.

Opoku-Mensah FA, Ahenkan A, Temesgen B, Maloreh-Nyamekye T. Opoku-Mensah FA, et al. Cost Eff Resour Alloc. 2025 Dec 9;24(1):6. doi: 10.1186/s12962-025-00686-w. Cost Eff Resour Alloc. 2025. PMID: 41366401 Free PMC article.

54

Post-COVID-19 condition patients' utilisation of healthcare resources after implementation of an integrated care unit.

Vicente-Gómez JÁ, de Muniategui Climente M, Loste C, Barreales S, Ríos LR, Paredes R, Mateu L, Segui FL. Vicente-Gómez JÁ, et al. Cost Eff Resour Alloc. 2025 Dec 2;23(1):72. doi: 10.1186/s12962-025-00667-z. Cost Eff Resour Alloc. 2025. PMID: 41331825 Free PMC article.

55

Intradermal hepatitis B vaccination with imiquimod pretreatment in dialysis patients: a cost-effectiveness analysis.

Wang Y, Rui M, You JHS. Wang Y, et al. Cost Eff Resour Alloc. 2025 Dec 2;24(1):4. doi: 10.1186/s12962-025-00682-0. Cost Eff Resour Alloc. 2025. PMID: 41331649 Free PMC article.

56

Economic burden of sports injury in China: result from a single center of medical quality and safety monitor system.

Mok TN, Huang Z, Ruoyu N, Guan J, Zhao J, Chen Z, Cheang LH, Tam MS, Fan D, Yeh TC, Li S, Wang H, Zheng X, Ming WK. Mok TN, et al. Cost Eff Resour Alloc. 2025 Dec 2;24(1):3. doi: 10.1186/s12962-025-00659-z. Cost Eff Resour Alloc. 2025. PMID: 41331465 Free PMC article.

57

Expenditure and use on radiology imaging in urban and rural areas in a developing country.

Espinosa O, Puentes G, Bejarano V, Romero J, Arias ML, Hedgire S, Daye D, Mohan S, Duszak R. Espinosa O, et al. Cost Eff Resour Alloc. 2025 Nov 27;23(1):74. doi: 10.1186/s12962-025-00681-1. Cost Eff Resour Alloc. 2025. PMID: 41310666 Free PMC article.

58

Analysis on the individual and allocation efficiencies of health resources in China: 2008-2021.

Liu Q, Zhou L. Liu Q, et al. Cost Eff Resour Alloc. 2025 Nov 26;23(1):70. doi: 10.1186/s12962-025-00675-z. Cost Eff Resour Alloc. 2025. PMID: 41299689 Free PMC article.

59

Cost-effectiveness analysis of gene-expression-based prognostic tests for patients with early-stage breast cancer in South Korea.

Kang D, Lim J, Kim L, Choi SE. Kang D, et al. Cost Eff Resour Alloc. 2025 Nov 26;24(1):1. doi: 10.1186/s12962-025-00679-9. Cost Eff Resour Alloc. 2025. PMID: 41299563 Free PMC article.

60

Key factors associated with China's basic medical insurance fund revenue-expenditure balance: a grey relational analysis.

Gong G, Dan W, Wei H, Xiping L. Gong G, et al. Cost Eff Resour Alloc. 2025 Nov 25;23(1):69. doi: 10.1186/s12962-025-00670-4. Cost Eff Resour Alloc. 2025. PMID: 41291777 Free PMC article.

61

Clinical, humanistic, and economic burden of systemic lupus erythematosus in the Kingdom of Saudi Arabia.

Al-Jedai A, Al-Mudaiheem H, Ghanim NA, Eshmawi M, AlHomood I, Dhopte P, Ojeil R. Al-Jedai A, et al. Cost Eff Resour Alloc. 2025 Nov 25;23(1):71. doi: 10.1186/s12962-025-00678-w. Cost Eff Resour Alloc. 2025. PMID: 41291703 Free PMC article. Review.

62

Cost-effectiveness protocol for treating adult HIV-infected patients with Kaposi sarcoma in resource-limited settings: a phase III, randomized, open-label, non-inferiority study of paclitaxel and pegylated liposomal doxorubicin.

Chapola JC, Kleber SL, Krown SE, Painschab M. Chapola JC, et al. Cost Eff Resour Alloc. 2025 Nov 24;23(1):78. doi: 10.1186/s12962-025-00677-x. Cost Eff Resour Alloc. 2025. PMID: 41286911 Free PMC article.

63

Cost-effectiveness analysis of second intravenous immunoglobulin infusion versus infliximab for treating IVIG-resistant Kawasaki disease patients.

Johnson JM, Simpson KN, Simpson AN, Tremoulet AH, Burns JC. Johnson JM, et al. Cost Eff Resour Alloc. 2025 Nov 22;23(1):76. doi: 10.1186/s12962-025-00674-0. Cost Eff Resour Alloc. 2025. PMID: 41275214 Free PMC article.

64

Fair pricing, fair access; a systematic review of cost-effectiveness of new hyperlipidemia injectable medication in developing countries.

Azari S, Pourasghari H, Rezaei MA, Behzadifar M, Salehbeigi S, Rajaei S, Jafarzadeh D, Soleimanpour S, Tajdini M. Azari S, et al. Cost Eff Resour Alloc. 2025 Nov 21;23(1):68. doi: 10.1186/s12962-025-00671-3. Cost Eff Resour Alloc. 2025. PMID: 41272757 Free PMC article. Review.

65

Economic analyses of freestyle libre systems for people living with diabetes: a systematic literature review.

de Pouvourville G, Timmons J, Levrat-Guillen F, Zara A, Poon Y. de Pouvourville G, et al. Cost Eff Resour Alloc. 2025 Nov 19;23(1):67. doi: 10.1186/s12962-025-00673-1. Cost Eff Resour Alloc. 2025. PMID: 41257727 Free PMC article. Review.

66

A cost-utility analysis of Glecaprevir/Pibrentasvir versus Sofosbuvir/Daclatasvir and Sofosbuvir/Velpatasvir for treatment of hepatitis C in Iran.

Jafari M, Mehdizadeh P, Keshavarz K, Teymourzadeh E, Abyazi MA, Alavian SM, Pouria A. Jafari M, et al. Cost Eff Resour Alloc. 2025 Nov 18;23(1):66. doi: 10.1186/s12962-025-00656-2. Cost Eff Resour Alloc. 2025. PMID: 41254760 Free PMC article.

67

Early versus delayed enteral nutrition in critically ill children under 12 years of age: an economic evaluation.

Manthalu G, Mpando T, Kredo T, Vorster P, Arikpo D, Brand A, Bango F, Mbeye N, Naude C, Nkonki L. Manthalu G, et al. Cost Eff Resour Alloc. 2025 Nov 11;23(1):65. doi: 10.1186/s12962-025-00668-y. Cost Eff Resour Alloc. 2025. PMID: 41219912 Free PMC article.

68

Cost-effectiveness analysis of Anastrozole combined with Abemaciclib for the treatment of postmenopausal hormone receptor-positive advanced breast cancer.

Lin X, Lan Y, Wang J, Zhao W, Liu X, Huang Z. Lin X, et al. Cost Eff Resour Alloc. 2025 Nov 10;23(1):64. doi: 10.1186/s12962-025-00605-z. Cost Eff Resour Alloc. 2025. PMID: 41214676 Free PMC article.

69

Cost-effectiveness of RefluxStop compared to proton pump inhibitors and Nissen fundoplication for management of persistent gastroesophageal reflux disease in Norway.

Harper S, Kartha M, Mealing S, Eftang L, Gaupset R. Harper S, et al. Cost Eff Resour Alloc. 2025 Oct 29;23(1):63. doi: 10.1186/s12962-025-00665-1. Cost Eff Resour Alloc. 2025. PMID: 41163234 Free PMC article.

70

Impact of national volume-based procurement reform on the markup of pharmaceutical firms: an event study.

Yan R, Miao Z, Cao F. Yan R, et al. Cost Eff Resour Alloc. 2025 Oct 29;23(1):62. doi: 10.1186/s12962-025-00664-2. Cost Eff Resour Alloc. 2025. PMID: 41163213 Free PMC article.

71

Do medicine prices reflect therapeutic value? Evidence from a comparison of the United Arab Emirates and Australia.

Ashraf A, Sim R, Ong SC. Ashraf A, et al. Cost Eff Resour Alloc. 2025 Oct 28;23(1):61. doi: 10.1186/s12962-025-00669-x. Cost Eff Resour Alloc. 2025. PMID: 41152960 Free PMC article.

72

The crucial role of early diagnosis for patients and the nation, understanding the costs of late-stage cancer diagnosis from a large district general hospital in England.

Butnari V, Scantlebury P, Green T, Pattni D, Mansuri A, Chinnery W, Rajendran N, Brannan M, Cole M, Banerjee S. Butnari V, et al. Cost Eff Resour Alloc. 2025 Oct 28;23(1):60. doi: 10.1186/s12962-025-00657-1. Cost Eff Resour Alloc. 2025. PMID: 41152849 Free PMC article.

73

Direct medical cost analysis of breast cancer treatment at Jimma University Medical Center: a provider perspective.

Edessa GJ, Kare KA, Edessa AJ, Daka DW. Edessa GJ, et al. Cost Eff Resour Alloc. 2025 Oct 27;23(1):59. doi: 10.1186/s12962-025-00666-0. Cost Eff Resour Alloc. 2025. PMID: 41146283 Free PMC article.

74

Analysis of human disease burden, determinants of treatment costs and affordability perceptions in the Rwenzori region, Uganda using DALYs, OLS and Bayesian regression.

Akugizibwe E, Ndungo I, Mpungu K, Mulinzi S, Karahukayo J. Akugizibwe E, et al. Cost Eff Resour Alloc. 2025 Oct 21;23(1):58. doi: 10.1186/s12962-025-00663-3. Cost Eff Resour Alloc. 2025. PMID: 41121379 Free PMC article.

75

Cost-effectiveness of ceftolozane/tazobactam compared to meropenem in ventilator-associated pneumonia.

Buendía JA, Patiño DG, Zuluaga Salazar AF. Buendía JA, et al. Cost Eff Resour Alloc. 2025 Oct 17;23(1):57. doi: 10.1186/s12962-025-00658-0. Cost Eff Resour Alloc. 2025. PMID: 41107993 Free PMC article.

76

A health economics assessment of self-care with over-the-counter ibuprofen in dysmenorrhoea, migraine and acute rhinosinusitis in the United Kingdom.

Afonso D, Dymond A, Eastwood I, Green W, Laughey W, Aluko P, Pennick G, Lodhi I, Charlesworth B. Afonso D, et al. Cost Eff Resour Alloc. 2025 Oct 15;23(1):56. doi: 10.1186/s12962-025-00660-6. Cost Eff Resour Alloc. 2025. PMID: 41094660 Free PMC article.

77

Cost-effectiveness analysis of an implantable cardiac defibrillator compared with pharmaceutical therapy in patients hospitalized with arrhythmia in Iran.

Nowruzi T, Goudarzi R, Aliramezany M, Moghadam MH, Bazmandegan G, Najafi S. Nowruzi T, et al. Cost Eff Resour Alloc. 2025 Oct 15;23(1):55. doi: 10.1186/s12962-025-00661-5. Cost Eff Resour Alloc. 2025. PMID: 41094500 Free PMC article.

78

Cost-effectiveness analysis of third-generation heat and moisture exchangers in patients who underwent laryngectomy in Japan.

Oridate N, Smedby T, Ruzza C, Roth M, Mehta M, Akachi Y, Skovgaard R, Itagaki T. Oridate N, et al. Cost Eff Resour Alloc. 2025 Oct 14;23(1):54. doi: 10.1186/s12962-025-00662-4. Cost Eff Resour Alloc. 2025. PMID: 41088476 Free PMC article.

79

Artificial intelligence applications in health insurances: a scoping review.

Ramezani-A M, Bakhtiari A, Mobinizadeh M, Daroudi R, Rabiee HR, Olyaeemanesh A, Fazaeli AA, Mostafavi H, Ramezani-B M, Sazgarnejad S, Bordbar S, Takian A. Ramezani-A M, et al. Cost Eff Resour Alloc. 2025 Oct 6;23(1):53. doi: 10.1186/s12962-025-00640-w. Cost Eff Resour Alloc. 2025. PMID: 41053747 Free PMC article. Review.

80

Cost-effectiveness of dienogest compared to gonadotropin releasing hormone agonists for the management of endometriosis in Vietnam.

Kieu MTT, Le MH, Nguyen CP. Kieu MTT, et al. Cost Eff Resour Alloc. 2025 Sep 29;23(1):51. doi: 10.1186/s12962-025-00655-3. Cost Eff Resour Alloc. 2025. PMID: 41024074 Free PMC article.

81

Disease-specific distress healthcare financing and catastrophic out-of-pocket expenditure for hospitalization care in Bangladesh.

Sarker AR, Hasan A, Islam R. Sarker AR, et al. Cost Eff Resour Alloc. 2025 Sep 29;23(1):52. doi: 10.1186/s12962-025-00627-7. Cost Eff Resour Alloc. 2025. PMID: 41024032 Free PMC article.

82

Study of direct costs of children hospitalized with opium poisoning: a case study of Iran.

Razmi M, Yusefzadeh H, Rostamzadeh N. Razmi M, et al. Cost Eff Resour Alloc. 2025 Sep 26;23(1):49. doi: 10.1186/s12962-025-00654-4. Cost Eff Resour Alloc. 2025. PMID: 41013645 Free PMC article.

83

Cost-effectiveness analysis of the SHaPED trial testing a multifaceted implementation strategy of a model of care to improve emergency department care of low back pain.

Coombs D, Lung T, Pinheiro MB, Howard K, Maher CG, Richards B, Needs C, Storey H, Machado GC. Coombs D, et al. Cost Eff Resour Alloc. 2025 Sep 26;23(1):50. doi: 10.1186/s12962-025-00652-6. Cost Eff Resour Alloc. 2025. PMID: 41013563 Free PMC article.

84

Economic evaluation of generic inhalational bronchodilators from the Jan-Aushadi scheme versus branded alternatives.

James J, Vinod NP, Manohar MM, Kumaran B R. James J, et al. Cost Eff Resour Alloc. 2025 Sep 26;23(1):48. doi: 10.1186/s12962-025-00648-2. Cost Eff Resour Alloc. 2025. PMID: 41013495 Free PMC article.

85

Economic evaluation of three domestic bevacizumab biosimilars and the original bevacizumab for treating nonsquamous non-small cell lung cancer in china: a cost-effectiveness analysis.

Zhang Y, Zhou T, Wu N, Bai Z, Wei J, Cai N, Xu S. Zhang Y, et al. Cost Eff Resour Alloc. 2025 Sep 26;23(1):47. doi: 10.1186/s12962-025-00653-5. Cost Eff Resour Alloc. 2025. PMID: 41013454 Free PMC article.

86

How to improve the construction efficiency of key medical disciplines: a three-stage DEA.

Sun H, Yu X, Li F, Zhang T, Song J, Du Y, Liu H. Sun H, et al. Cost Eff Resour Alloc. 2025 Sep 24;23(1):46. doi: 10.1186/s12962-025-00649-1. Cost Eff Resour Alloc. 2025. PMID: 40993710 Free PMC article.

87

Prolonged intermittent home video-EEG monitoring for drug-resistant epilepsy: the cost-availability model.

Vander T, Stroganova T, Bikmullina R, Balberg M, Benoliel T, Gilboa T, Medvedovsky M. Vander T, et al. Cost Eff Resour Alloc. 2025 Sep 2;23(1):45. doi: 10.1186/s12962-025-00650-8. Cost Eff Resour Alloc. 2025. PMID: 40898222 Free PMC article.

88

Cost-effectiveness analysis of a community pharmacist-based intervention to prevent cardiovascular complications in patients with type 2 diabetes in Iran.

Ghasemi Z, Mousa R, Peiravian F, Yousefi N. Ghasemi Z, et al. Cost Eff Resour Alloc. 2025 Aug 29;23(1):44. doi: 10.1186/s12962-025-00651-7. Cost Eff Resour Alloc. 2025. PMID: 40883843 Free PMC article.

89

Cost effectiveness of mono, dual, and triple therapy of antihypertensive drugs: a retrospective cohort study.

Abdullah, Asim Z. Abdullah, et al. Cost Eff Resour Alloc. 2025 Aug 14;23(1):43. doi: 10.1186/s12962-025-00614-y. Cost Eff Resour Alloc. 2025. PMID: 40813675 Free PMC article.

90

Out-of-pocket costs, time burden, and caregiver quality of life associated with pediatric medically attended respiratory syncytial virus illnesses.

Rose AM, Mercon KR, Gebremariam A, Pike J, Prosser LA. Rose AM, et al. Cost Eff Resour Alloc. 2025 Aug 12;23(1):42. doi: 10.1186/s12962-025-00646-4. Cost Eff Resour Alloc. 2025. PMID: 40797217 Free PMC article.

91

A gender perspective of smoking cessation's health and economic value in Jordanian women: using cost effectiveness model.

Madae'en S, Obeidat N, Haddad M, Alrosan K, Alrosan AZ, Shaggour B, Madain R, Matanes F. Madae'en S, et al. Cost Eff Resour Alloc. 2025 Aug 7;23(1):41. doi: 10.1186/s12962-025-00636-6. Cost Eff Resour Alloc. 2025. PMID: 40775783 Free PMC article.

92

Pioneering SMA therapies for all types: survival gains, cost dynamics, and performance-based agreements.

Al-Jedai A, Al-Mudaiheem H, AlSakran A, Bashiri FA, Ghamdi F, Almuhaizea MA, AlSamman A, Awad N, Ojeil R. Al-Jedai A, et al. Cost Eff Resour Alloc. 2025 Aug 5;23(1):40. doi: 10.1186/s12962-025-00647-3. Cost Eff Resour Alloc. 2025. PMID: 40765022 Free PMC article.

93

Strategic analysis of financing communicable diseases in Afghanistan.

Hayat E, Neyazi N, Dargahi H, Jaafaripooyan E, Mosadeghrad AM. Hayat E, et al. Cost Eff Resour Alloc. 2025 Aug 4;23(1):39. doi: 10.1186/s12962-025-00634-8. Cost Eff Resour Alloc. 2025. PMID: 40760491 Free PMC article.

94

Exploring patient's clinical outcomes, hospital costs, and satisfaction after the implementation of integrated clinical pathway-based nursing practice model.

Rachmawaty R, Wahyudin E, Bukhari A. Rachmawaty R, et al. Cost Eff Resour Alloc. 2025 Jul 30;23(1):38. doi: 10.1186/s12962-025-00645-5. Cost Eff Resour Alloc. 2025. PMID: 40739272 Free PMC article.

95

Cost-utility analysis of omalizumab for the treatment of chronic spontaneous urticaria in China.

Huang Y, Yuan H, Huang Z. Huang Y, et al. Cost Eff Resour Alloc. 2025 Jul 22;23(1):37. doi: 10.1186/s12962-025-00643-7. Cost Eff Resour Alloc. 2025. PMID: 40696383 Free PMC article.

96

The cost of delivering COVID-19 vaccines in four districts in Malawi.

Ruisch A, Ntopi S, Mathur I, Conlin M, McCaffrey A, Walker DG, Suharlim C. Ruisch A, et al. Cost Eff Resour Alloc. 2025 Jul 22;23(1):36. doi: 10.1186/s12962-025-00610-2. Cost Eff Resour Alloc. 2025. PMID: 40696382 Free PMC article.

97

Regional disparities, dynamic evolution, and spatial spillover effects of medical resource allocation efficiency in TCM hospitals.

Wang Z, Li Z, Xie R. Wang Z, et al. Cost Eff Resour Alloc. 2025 Jul 18;23(1):35. doi: 10.1186/s12962-025-00644-6. Cost Eff Resour Alloc. 2025. PMID: 40682090 Free PMC article.

98

Cost-effectiveness of dabigatran for thromboembolic events prevention in atrial fibrillation patients in Chile.

Abbot T, Armijo N, Orellana LR, Jiménez AG, Balmaceda C, Espinoza M. Abbot T, et al. Cost Eff Resour Alloc. 2025 Jul 7;23(1):34. doi: 10.1186/s12962-025-00642-8. Cost Eff Resour Alloc. 2025. PMID: 40624582 Free PMC article.

99

Prescription cost analysis and economic impact of drug treatment in patients with chronic illness, attending the medicine out-patient department in a tertiary care hospital at South Delhi.

Nabi N, Manghani A, Uddin A, Dhillon N, Singh D, Chandra K, Jain V, Jain R, Ahmad R, Kohli S. Nabi N, et al. Cost Eff Resour Alloc. 2025 Jun 20;23(1):33. doi: 10.1186/s12962-025-00628-6. Cost Eff Resour Alloc. 2025. PMID: 40542383 Free PMC article.

100

Handling uncertainty in cost-effectiveness analysis in dental medicine: a systematic review with a focus on affordability and risk-aversion.

Sendi P, Walterscheidt M, Bornstein MM. Sendi P, et al. Cost Eff Resour Alloc. 2025 Jun 19;23(1):32. doi: 10.1186/s12962-025-00641-9. Cost Eff Resour Alloc. 2025. PMID: 40537795 Free PMC article. Review.

101

Healthcare professionals' perceptions of electronic prescription systems in outpatient services: a qualitative study at UNS hospital.

Sudarsono J, Satibi S, Lazuardi L, Widayanti AW. Sudarsono J, et al. Cost Eff Resour Alloc. 2025 Jun 18;23(1):31. doi: 10.1186/s12962-025-00639-3. Cost Eff Resour Alloc. 2025. PMID: 40533799 Free PMC article.

102

The effect of family physician program and health transformation plan on utilization and cost of health services.

Safarpoor Z, Lotfi F, Bayati M, Moordzade H, Goudarzi Z, Keshavarz K. Safarpoor Z, et al. Cost Eff Resour Alloc. 2025 Jun 16;23(1):30. doi: 10.1186/s12962-025-00637-5. Cost Eff Resour Alloc. 2025. PMID: 40524174 Free PMC article.

103

Pembrolizumab plus chemotherapy in advanced endometrial cancer: a cost-effectiveness analysis.

Zhao X, She L, Liu X, Bi Z. Zhao X, et al. Cost Eff Resour Alloc. 2025 Jun 12;23(1):29. doi: 10.1186/s12962-025-00625-9. Cost Eff Resour Alloc. 2025. PMID: 40506696 Free PMC article.

104

Global, regional, and national burden of epilepsy, 1990-2021: a systematic analysis for the Global Burden of Disease Study in 2021.

Sun T, Yu T, Liu P. Sun T, et al. Cost Eff Resour Alloc. 2025 Jun 11;23(1):28. doi: 10.1186/s12962-025-00635-7. Cost Eff Resour Alloc. 2025. PMID: 40500766 Free PMC article.

105

Review for cost-effectiveness analysis of laparoscopic Intra-peritoneal Onlay Mesh for ventral hernia repair in Indian settings.

Guleria C, Kumar D, Sahoo KC. Guleria C, et al. Cost Eff Resour Alloc. 2025 Jun 10;23(1):27. doi: 10.1186/s12962-025-00638-4. Cost Eff Resour Alloc. 2025. PMID: 40495189 Free PMC article. Review.

106

Cost-effectiveness analysis of a new paradigm to simplify testing, monitoring and treatment of hepatitis C virus in the United States.

Dietrich D, Reau N, Ahmed A, Blissett R, Igloi-Nagy A, Yehoshua A. Dietrich D, et al. Cost Eff Resour Alloc. 2025 Jun 4;23(1):25. doi: 10.1186/s12962-025-00622-y. Cost Eff Resour Alloc. 2025. PMID: 40468418 Free PMC article.

107

Cost-effectiveness of myopia-control spectacles and contact lenses for children and adolescents in Wales.

Bennett H, Britton A, O'Sullivan D, Lado F. Bennett H, et al. Cost Eff Resour Alloc. 2025 Jun 4;23(1):26. doi: 10.1186/s12962-025-00632-w. Cost Eff Resour Alloc. 2025. PMID: 40468291 Free PMC article.

108

A cost-effectiveness analysis of two psychological treatments for controlled drinking in individuals alcohol use disorder.

Flores S, Jónsson-Bachmann E, Ingesson-Hammarberg S, Hammarberg A, Nystrand C, Sampaio F. Flores S, et al. Cost Eff Resour Alloc. 2025 Jun 2;23(1):24. doi: 10.1186/s12962-025-00633-9. Cost Eff Resour Alloc. 2025. PMID: 40457439 Free PMC article.

109

Analysis of costs in implementing the HEARTS hypertension program in Nigerian primary care.

Sambo EN, Husain MJ, Basu S, Toma MM, Eze SV, Osi K, Ogbureke N, Erojikwe O, Banigbe B, Moran AE, Kostova D. Sambo EN, et al. Cost Eff Resour Alloc. 2025 May 27;23(1):23. doi: 10.1186/s12962-025-00626-8. Cost Eff Resour Alloc. 2025. PMID: 40426221 Free PMC article.

110

The effect of hospital budgeting system on physician-executives' budget cognitive consciousness and medical decision making.

Huang WH, Lu CT. Huang WH, et al. Cost Eff Resour Alloc. 2025 May 21;23(1):22. doi: 10.1186/s12962-025-00629-5. Cost Eff Resour Alloc. 2025. PMID: 40400001 Free PMC article.

111

Estimation of economic burden of high salt intake in cardiovascular disease attributed to hypertension in Iran.

Pourkhajoei S, Goudarzi R, Amiresmaeili M, Nakhaee N, Yazdi-Feyzabadi V. Pourkhajoei S, et al. Cost Eff Resour Alloc. 2025 May 20;23(1):21. doi: 10.1186/s12962-025-00631-x. Cost Eff Resour Alloc. 2025. PMID: 40394617 Free PMC article.

112

Optimizing strategy for cervical cancer prevention in china: a comprehensive modeling analysis.

Zhou D, Zhang D, Wang Y, Zhou K, Tang W. Zhou D, et al. Cost Eff Resour Alloc. 2025 May 14;23(1):20. doi: 10.1186/s12962-025-00630-y. Cost Eff Resour Alloc. 2025. PMID: 40369618 Free PMC article.

113

Effectiveness analysis and value incommensurability.

Herlitz A. Herlitz A. Cost Eff Resour Alloc. 2025 Apr 23;23(1):19. doi: 10.1186/s12962-025-00624-w. Cost Eff Resour Alloc. 2025. PMID: 40269918 Free PMC article.

114

Impact of China's diagnosis-intervention packet payment reform on pediatric pneumonia hospitalization costs: an interrupted time series analysis.

Zhao L, Zeng K, Chen F, Li W, Zhao J. Zhao L, et al. Cost Eff Resour Alloc. 2025 Apr 21;23(1):18. doi: 10.1186/s12962-025-00623-x. Cost Eff Resour Alloc. 2025. PMID: 40259332 Free PMC article.

115

Out-of-pocket pharmaceutical expenditure and potential misuse of public resources - analysis in the Italian context.

Maurmo L, Ruta F, Dicuonzo G, Signoretta V, Gennari C, Dicuonzo V, Suma D, D'Ambrosio M, Procacci C. Maurmo L, et al. Cost Eff Resour Alloc. 2025 Apr 17;23(1):17. doi: 10.1186/s12962-025-00619-7. Cost Eff Resour Alloc. 2025. PMID: 40247361 Free PMC article.

116

Cost-utility analysis of olaparib assisted targeted therapy for BRCA mutation HER2-negative early breast cancer in China and in the United States.

Xu C, Zhuang J, Shen J, Sun H, Cai J, Wei X. Xu C, et al. Cost Eff Resour Alloc. 2025 Apr 13;23(1):16. doi: 10.1186/s12962-025-00617-9. Cost Eff Resour Alloc. 2025. PMID: 40223109 Free PMC article.

117

Health economic evaluation of trans-tibial prosthetic suspension systems: a protocol for a pilot using an observational study and synthetic cohort.

Clarke L, Shiell A, Dillon MP. Clarke L, et al. Cost Eff Resour Alloc. 2025 Apr 12;23(1):15. doi: 10.1186/s12962-025-00611-1. Cost Eff Resour Alloc. 2025. PMID: 40221702 Free PMC article.

118

Cost-effectiveness analysis of nephroprotection programs for patients with type 2 diabetes mellitus in insurers in Colombia.

González-Rojas CA, Cáceres-Maldonado SA, Soler-Vanoy LA, Acuña-Merchán LA. González-Rojas CA, et al. Cost Eff Resour Alloc. 2025 Apr 12;23(1):14. doi: 10.1186/s12962-025-00618-8. Cost Eff Resour Alloc. 2025. PMID: 40217283 Free PMC article.

119

A systematic review of the current application status of decision-analytical models in the pharmacoeconomic evaluation of targeted therapies for pulmonary arterial hypertension.

Dong W, Zhang Z, Wang X, Ma X, Chu M, Li Y, Xiang X, Peng C, Zhang R. Dong W, et al. Cost Eff Resour Alloc. 2025 Apr 11;23(1):13. doi: 10.1186/s12962-025-00621-z. Cost Eff Resour Alloc. 2025. PMID: 40217322 Free PMC article.

120

Willingness to join community-based health insurance and associated factors among households in Ethiopian: a systematic review and meta-analysis.

Kaso AW, Debela BG, Hareru HE, Ewune HA, Debisa MA, Sisay D, Hailu A. Kaso AW, et al. Cost Eff Resour Alloc. 2025 Apr 10;23(1):12. doi: 10.1186/s12962-025-00620-0. Cost Eff Resour Alloc. 2025. PMID: 40211299 Free PMC article. Review.

121

Association between medical insurance and life satisfaction among middle-aged and older adults in China: the mediating role of depression.

Sun J, Coyte PC, Liu Y, Wang Q. Sun J, et al. Cost Eff Resour Alloc. 2025 Apr 10;23(1):10. doi: 10.1186/s12962-024-00584-7. Cost Eff Resour Alloc. 2025. PMID: 40205490 Free PMC article.

122

Operationalizing game-theoretic weighting in public hospital cost control: an implementation framework from Chinese tertiary hospitals.

Yu Z, Sun G, Lin S, Hu H, Xu J. Yu Z, et al. Cost Eff Resour Alloc. 2025 Mar 31;23(1):11. doi: 10.1186/s12962-025-00616-w. Cost Eff Resour Alloc. 2025. PMID: 40165320 Free PMC article.

123

A cost-utility analysis of long-acting insulin analogues (detemir, glargine and degludec) for the treatment of adult type 1 diabetes in South Africa.

Verryn MT, Cleary S. Verryn MT, et al. Cost Eff Resour Alloc. 2025 Mar 23;23(1):9. doi: 10.1186/s12962-025-00615-x. Cost Eff Resour Alloc. 2025. PMID: 40122825 Free PMC article.

124

Cost-effectiveness of sacituzumab govitecan for hormone receptor-positive human epidermal growth factor receptor 2-negative metastatic breast cancer based on the EVER-132-002 trial in China.

Liu S, Wang K, Chen H, Wan Z, Dou L, Li S. Liu S, et al. Cost Eff Resour Alloc. 2025 Mar 19;23(1):8. doi: 10.1186/s12962-025-00613-z. Cost Eff Resour Alloc. 2025. PMID: 40108623 Free PMC article.

125

Factors influencing the demand for individual voluntary private health insurance in Iran.

Daroudi R, Hashempour R, Raei B, Ramandi S, Irandoust K, Kazemi-Karyani A, Abolhasanbeigi Gallehzan N, Yahyavi Dizaj J, Darabi M. Daroudi R, et al. Cost Eff Resour Alloc. 2025 Mar 17;23(1):7. doi: 10.1186/s12962-025-00609-9. Cost Eff Resour Alloc. 2025. PMID: 40098020 Free PMC article.

126

Third-line multiple myeloma treatment of inpatients in a German cancer center: analysis of potential cost savings due to decreased renal insufficiency.

Jakobs F, Ahmadi P, Osterkamp V, Jeck J, Holtick U, Scheid C, Kron F. Jakobs F, et al. Cost Eff Resour Alloc. 2025 Mar 5;23(1):6. doi: 10.1186/s12962-024-00600-w. Cost Eff Resour Alloc. 2025. PMID: 40045293 Free PMC article.

127

Cost-effectiveness of nirmatrelvir/ritonavir in COVID-19 patient groups at high risk for progression to severe COVID-19 in the Netherlands.

Arteaga Duarte CH, Peters ML, de Goeij MHM, Spijkerman R, Postma MJ. Arteaga Duarte CH, et al. Cost Eff Resour Alloc. 2025 Feb 24;23(1):5. doi: 10.1186/s12962-025-00604-0. Cost Eff Resour Alloc. 2025. PMID: 39994707 Free PMC article.

128

Comparative Efficiency Analysis of OECD Health Systems: FDH vs. Machine Learning Approaches with Efficiency Analysis Trees (EAT and RFEAT).

Joo Y. Joo Y. Cost Eff Resour Alloc. 2025 Feb 22;23(1):4. doi: 10.1186/s12962-025-00607-x. Cost Eff Resour Alloc. 2025. PMID: 39987237 Free PMC article.

129

The cost-effectiveness analysis of newborn screening for inherited metabolic disorders in China using tandem mass spectrometry: a real-world evidence.

Xiao D, Yuan J, Liu S, Yang Y, Chen Y. Xiao D, et al. Cost Eff Resour Alloc. 2025 Feb 19;23(1):3. doi: 10.1186/s12962-025-00608-w. Cost Eff Resour Alloc. 2025. PMID: 39972330 Free PMC article.

130

The effect of Covid-19 pandemic on the primary health care utilization and cost: an interrupted time series analysis.

Bayati M, Lotfi F, Bayati M, Goudarzi Z. Bayati M, et al. Cost Eff Resour Alloc. 2025 Feb 12;23(1):2. doi: 10.1186/s12962-025-00606-y. Cost Eff Resour Alloc. 2025. PMID: 39939987 Free PMC article.

131

Cost-effectiveness and budget impact of covering Burkitt lymphoma in children under Ghana's National Health Insurance Scheme.

Owusu R, Pritchard D, Heupink LF, Gulbi G, Asare B, Amankwah I, Azeez J, Gyansa-Lutterodt M, Dsane-Selby L, Mensah RA, Omane-Adjekum W, Ruiz F, Gad M, Nonvignon J, Chola L; Ghana Health Technology Assessment Technical Working Group. Owusu R, et al. Cost Eff Resour Alloc. 2025 Jan 27;23(1):1. doi: 10.1186/s12962-025-00603-1. Cost Eff Resour Alloc. 2025. PMID: 39871292 Free PMC article.

132

Validation of the PECUNIA reference unit costs templates in Spain: a useful tool for multi-national economic evaluations of health technologies.

García-Pérez L, Linertová R, Hernández-Yumar A, Valcárcel-Nazco C, Perdomo-Vielma J, Serrano-Aguilar P, Gutierrez-Colosia MR, Salvador-Carulla L, Fernández-Vega E, Mayer S, Simon J; PECUNIA Group. García-Pérez L, et al. Cost Eff Resour Alloc. 2024 Dec 18;22(1):92. doi: 10.1186/s12962-024-00601-9. Cost Eff Resour Alloc. 2024. PMID: 39696415 Free PMC article.

133

Itemized point cost method in human resource cost accounting in medical service projects.

Li Y, Liang S, Qin K, Su H, Xia P. Li Y, et al. Cost Eff Resour Alloc. 2024 Dec 18;22(1):91. doi: 10.1186/s12962-024-00599-0. Cost Eff Resour Alloc. 2024. PMID: 39695739 Free PMC article.

134

IAPN: a simple framework for evaluating whether a population-based risk stratification tool will be cost-effective before implementation.

Wyatt S, Mohammed MA, Spilsbury P. Wyatt S, et al. Cost Eff Resour Alloc. 2024 Dec 4;22(1):90. doi: 10.1186/s12962-024-00594-5. Cost Eff Resour Alloc. 2024. PMID: 39633403 Free PMC article.

135

Cost of the national malaria control program and cost-effectiveness of indoor residual spraying and insecticide-treated bed net interventions in two districts of Madagascar.

Andrianantoandro VTA, Audibert M, Kesteman T, Ravolanjarasoa L, Randrianarivelojosia M, Rogier C. Andrianantoandro VTA, et al. Cost Eff Resour Alloc. 2024 Dec 3;22(1):89. doi: 10.1186/s12962-024-00598-1. Cost Eff Resour Alloc. 2024. PMID: 39627788 Free PMC article.

136

Controversies in implementing the exemption policy for the elderly healthcare services in Tanzania: experiences from the priority setting process in two selected districts.

Tungu M, Sirili N, Kagaigai A, Luoga P, Tesha N, Ruwaichi T, Frumence G. Tungu M, et al. Cost Eff Resour Alloc. 2024 Dec 3;22(1):88. doi: 10.1186/s12962-024-00595-4. Cost Eff Resour Alloc. 2024. PMID: 39627777 Free PMC article.

137

Assessing diagnosis-related groups based direct medical expenditures of chronic disease patients in general hospital of lower southern Thailand.

Wongpairin A, Lim A, Tongkumchum P, Thongpeth W, Khurram H. Wongpairin A, et al. Cost Eff Resour Alloc. 2024 Nov 27;22(1):87. doi: 10.1186/s12962-024-00596-3. Cost Eff Resour Alloc. 2024. PMID: 39605031 Free PMC article.

138

Health system efficiency and equity in ASEAN: an empirical investigation.

Liu Y, Gong L, Niu H, Jiang F, Du S, Jiang Y. Liu Y, et al. Cost Eff Resour Alloc. 2024 Nov 26;22(1):86. doi: 10.1186/s12962-024-00588-3. Cost Eff Resour Alloc. 2024. PMID: 39587581 Free PMC article.

139

Coverage and distributional benefit-cost of rotavirus vaccine in Uganda: an analysis of routine health facility aggregated data.

Kananura RM, de Broucker G, Ssebagereka A, Mutebi A, Kiracho EE, Patenaude B. Kananura RM, et al. Cost Eff Resour Alloc. 2024 Nov 22;22(1):85. doi: 10.1186/s12962-024-00586-5. Cost Eff Resour Alloc. 2024. PMID: 39578806 Free PMC article.

140

Cost-effectiveness of fenofibrate for preventing diabetic complications in Australia.

Kim H, Lyu J, Raja V, Kim K. Kim H, et al. Cost Eff Resour Alloc. 2024 Nov 18;22(1):84. doi: 10.1186/s12962-024-00591-8. Cost Eff Resour Alloc. 2024. PMID: 39558204 Free PMC article.

141

Cost-effectiveness of high-dose vitamin D supplementation to reduce the occurrence of repeat episodes of pneumonia in children.

Buendía JA, Patiño DG. Buendía JA, et al. Cost Eff Resour Alloc. 2024 Nov 14;22(1):83. doi: 10.1186/s12962-024-00589-2. Cost Eff Resour Alloc. 2024. PMID: 39543659 Free PMC article.

142

Cost-effectiveness analysis of Tocilizumab compared to Adalimumab in the treatment of severe active rheumatoid arthritis in Iran.

Metghalchi Y, Yaghoubi N, Yousefi N, Ahmadi R, Kargar A, Zargaran M, Rezaei S. Metghalchi Y, et al. Cost Eff Resour Alloc. 2024 Nov 13;22(1):82. doi: 10.1186/s12962-024-00592-7. Cost Eff Resour Alloc. 2024. PMID: 39538256 Free PMC article.

143

From pilot to national roll-out of the improved Community Health Fund (iCHF) in Tanzania: lessons learnt and way forward.

Kapologwe NA, Marwa B, Marwa H, Kebby A, Kengia JT, Ruhago G, Kibusi SM, Mboya IB, Mtei G, Kalolo A. Kapologwe NA, et al. Cost Eff Resour Alloc. 2024 Nov 12;22(1):80. doi: 10.1186/s12962-024-00571-y. Cost Eff Resour Alloc. 2024. PMID: 39533367 Free PMC article.

144

Identifying and prioritizing inefficiency causes in Iran's health system.

Olyaeemanesh A, Habibi F, Mobinizadeh M, Takian A, Khosravi B, Jafarzadeh J, Bakhtiari A, Mohamadi E. Olyaeemanesh A, et al. Cost Eff Resour Alloc. 2024 Nov 12;22(1):81. doi: 10.1186/s12962-024-00593-6. Cost Eff Resour Alloc. 2024. PMID: 39533362 Free PMC article.

145

Correction: Global bibliometric analysis of cost effectiveness analysis in healthcare research from 2013 to 2023.

Okoroiwu KL, Okoroiwu HU, Ude LO, Ezuma CO, Omeje EI. Okoroiwu KL, et al. Cost Eff Resour Alloc. 2024 Nov 5;22(1):78. doi: 10.1186/s12962-024-00587-4. Cost Eff Resour Alloc. 2024. PMID: 39501391 Free PMC article. No abstract available.

146

Correction: The costs of implementing anaemia reduction interventions among women fish processors in Ghana.

Adane F, Aryeetey R, Aryeetey G, Nonvignon J. Adane F, et al. Cost Eff Resour Alloc. 2024 Nov 5;22(1):79. doi: 10.1186/s12962-024-00590-9. Cost Eff Resour Alloc. 2024. PMID: 39501316 Free PMC article. No abstract available.

147

The role of economic evaluation in modelling public health and social measures for pandemic policy: a systematic review.

Rossiter S, Howe S, Szanyi J, Trauer JM, Wilson T, Blakely T. Rossiter S, et al. Cost Eff Resour Alloc. 2024 Nov 1;22(1):77. doi: 10.1186/s12962-024-00585-6. Cost Eff Resour Alloc. 2024. PMID: 39487485 Free PMC article.

148

Financing immunisation in Kenya: examining bottlenecks in health sector planning and budgeting at the decentralised level.

Adjagba AO, Oguta JO, Akoth C, Wambiya EOA, Nonvignon J, Jackson D. Adjagba AO, et al. Cost Eff Resour Alloc. 2024 Oct 29;22(1):76. doi: 10.1186/s12962-024-00581-w. Cost Eff Resour Alloc. 2024. PMID: 39472992 Free PMC article.

149

A review on the evolving environment of medical device real-world evidence regulation on market access in the USA.

Shi L, Xuan D, Jakovljevic M. Shi L, et al. Cost Eff Resour Alloc. 2024 Oct 25;22(1):75. doi: 10.1186/s12962-024-00582-9. Cost Eff Resour Alloc. 2024. PMID: 39456032 Free PMC article. Review. No abstract available.

150

Economic burden of knee joint replacement in Iran.

Rajabi M, Pourahmadi E, Adel A, Kemmak AR. Rajabi M, et al. Cost Eff Resour Alloc. 2024 Oct 22;22(1):74. doi: 10.1186/s12962-024-00583-8. Cost Eff Resour Alloc. 2024. PMID: 39438951 Free PMC article.

151

Beneficiaries' satisfaction with community-based health insurance services and associated factors in Ethiopia: a systematic review and meta-analysis.

Bayked EM, Toleha HN, Zewdie S, Mekonen AM, Workneh BD, Kahissay MH. Bayked EM, et al. Cost Eff Resour Alloc. 2024 Oct 18;22(1):73. doi: 10.1186/s12962-024-00541-4. Cost Eff Resour Alloc. 2024. PMID: 39425215 Free PMC article. Review.

152

Exploring the potential cost-effectiveness of a new computerised decision support tool for identifying fetal compromise during monitored term labours: an early health economic model.

Campbell HE, Ratushnyak S, Georgieva A, Impey L, Rivero-Arias O. Campbell HE, et al. Cost Eff Resour Alloc. 2024 Oct 7;22(1):72. doi: 10.1186/s12962-024-00580-x. Cost Eff Resour Alloc. 2024. PMID: 39375735 Free PMC article.

153

Financial incentives in the management of diabetes: a systematic review.

Zhang Q, Wei X, Zheng J, Lu Y, Wu Y. Zhang Q, et al. Cost Eff Resour Alloc. 2024 Sep 27;22(1):71. doi: 10.1186/s12962-024-00579-4. Cost Eff Resour Alloc. 2024. PMID: 39334364 Free PMC article. Review.

154

Economic evaluation of NALIRIFOX vs. nab-paclitaxel and gemcitabine regimens for first-line treatment of metastatic pancreatic ductal adenocarcinoma from U.S. perspective.

Shao H, Fang H, Li Y, Jiang Y, Zhao M, Tang W. Shao H, et al. Cost Eff Resour Alloc. 2024 Sep 18;22(1):70. doi: 10.1186/s12962-024-00578-5. Cost Eff Resour Alloc. 2024. PMID: 39294689 Free PMC article.

155

The costs of implementing anaemia reduction interventions among women fish processors in Ghana.

Adane F, Aryeetey R, Aryeetey G, Nonvignon J. Adane F, et al. Cost Eff Resour Alloc. 2024 Sep 17;22(1):69. doi: 10.1186/s12962-024-00559-8. Cost Eff Resour Alloc. 2024. PMID: 39289741 Free PMC article.

156

Global bibliometric analysis of cost effectiveness analysis in healthcare research from 2013 to 2023.

Okoroiwu KL, Okoroiwu HU, Ude LO, Ezuma CO, Omeje EI. Okoroiwu KL, et al. Cost Eff Resour Alloc. 2024 Sep 16;22(1):68. doi: 10.1186/s12962-024-00576-7. Cost Eff Resour Alloc. 2024. PMID: 39278914 Free PMC article.

157

Technical efficiency of ghanaian health facilities before and during the COVID-19 pandemic.

Abekah-Nkrumah G, Ofori CG, Antwi M, Attachey AY, de Wit TFR, Janssens W, Duah J, Dieteren C, Sunkwa-Mills G. Abekah-Nkrumah G, et al. Cost Eff Resour Alloc. 2024 Sep 15;22(1):67. doi: 10.1186/s12962-024-00575-8. Cost Eff Resour Alloc. 2024. PMID: 39278903 Free PMC article.

158

Cost-effectiveness of proton beam therapy vs. conventional radiotherapy for patients with brain tumors in Sweden: results from a non-randomized prospective multicenter study.

Sampaio F, Langegård U, de Alva PM, Flores S, Nystrand C, Fransson P, Ohlsson-Nevo E, Kristensen I, Sjövall K, Feldman I, Ahlberg K. Sampaio F, et al. Cost Eff Resour Alloc. 2024 Sep 13;22(1):66. doi: 10.1186/s12962-024-00577-6. Cost Eff Resour Alloc. 2024. PMID: 39272105 Free PMC article.

159

Pharmacoeconomic evaluation of treatments for Poly Cystic Ovarian Syndrome (PCOS).

Masroor D, Khaliq SA, Ahmad SM, Mazhar F, Azhar I. Masroor D, et al. Cost Eff Resour Alloc. 2024 Sep 5;22(1):62. doi: 10.1186/s12962-024-00569-6. Cost Eff Resour Alloc. 2024. PMID: 39238017 Free PMC article.

160

Developing a systems-focused tool for modeling lung cancer screening resource needs.

Reddy A, Abe-Nornes F, Haskell A, Saito M, Schumacher M, Venkat A, Venkatasubramanian K, Woodhouse K, Zhang Y, Niktafar H, Leveque A, Kedroske B, Ramnath N, Cohn A. Reddy A, et al. Cost Eff Resour Alloc. 2024 Sep 5;22(1):63. doi: 10.1186/s12962-024-00573-w. Cost Eff Resour Alloc. 2024. PMID: 39237997 Free PMC article.

161

HPV vaccination strategy for 14-year-old females and economic returns for cervical cancer prevention in Wuxi City, China: a cost effectiveness analysis.

Jiang J, Zhao F, Hong X, Wang X. Jiang J, et al. Cost Eff Resour Alloc. 2024 Sep 5;22(1):64. doi: 10.1186/s12962-024-00574-9. Cost Eff Resour Alloc. 2024. PMID: 39237947 Free PMC article.

162

The direct cost of chronic kidney disease (CKD) reported in Asian countries; a systematic literature review.

Nisar M, Tasleem Z, Muhammad SA, Javid A, Rasool MF, Karuniawati H, Al-Tamimi SK, Rehman AU. Nisar M, et al. Cost Eff Resour Alloc. 2024 Sep 5;22(1):65. doi: 10.1186/s12962-024-00566-9. Cost Eff Resour Alloc. 2024. PMID: 39237946 Free PMC article.

163

Inequalities in health care use among patients with arthritis in China: using Andersen's Behavioral Model.

Liu J, Tang Y, Zheng P, Chen M, Si L. Liu J, et al. Cost Eff Resour Alloc. 2024 Aug 31;22(1):61. doi: 10.1186/s12962-024-00572-x. Cost Eff Resour Alloc. 2024. PMID: 39217335 Free PMC article.

164

Willingness to pay for cataract surgery and its associated factors in selected medical centers in Urmia, Iran.

Rahmanzadeh F, Alinia C, Fathi B, Yusefzadeh H. Rahmanzadeh F, et al. Cost Eff Resour Alloc. 2024 Aug 29;22(1):60. doi: 10.1186/s12962-024-00570-z. Cost Eff Resour Alloc. 2024. PMID: 39210446 Free PMC article.

165

Economic aspects of prolonged home video-EEG monitoring: a simulation study.

Vander T, Bikmullina R, Froimovich N, Stroganova T, Nissenkorn A, Gilboa T, Eliashiv D, Ekstein D, Medvedovsky M. Vander T, et al. Cost Eff Resour Alloc. 2024 Aug 10;22(1):59. doi: 10.1186/s12962-024-00568-7. Cost Eff Resour Alloc. 2024. PMID: 39127662 Free PMC article.

166

The efficiency of clinical laboratories: the case of Kerman province.

Shaker Z, Shaker Z, Barouni M, Sabermahani A. Shaker Z, et al. Cost Eff Resour Alloc. 2024 Aug 6;22(1):58. doi: 10.1186/s12962-024-00564-x. Cost Eff Resour Alloc. 2024. PMID: 39103861 Free PMC article.

167

The impacts of basic medical insurance for urban-rural residents on the perception of social equity in China.

Wang X, Chen X, Li L, Zhou D. Wang X, et al. Cost Eff Resour Alloc. 2024 Aug 3;22(1):57. doi: 10.1186/s12962-024-00565-w. Cost Eff Resour Alloc. 2024. PMID: 39097696 Free PMC article.

168

Cost and efficiency analysis in Iranian primary health centers: a micro costing and data envelopment analysis.

Mahboub-Ahar A, Khanlari S, Yusefzadeh H, Ghorbani A. Mahboub-Ahar A, et al. Cost Eff Resour Alloc. 2024 Aug 1;22(1):56. doi: 10.1186/s12962-024-00567-8. Cost Eff Resour Alloc. 2024. PMID: 39090621 Free PMC article.

169

The economic burden of bipolar disorder: a case study in Southern Iran.

Shaker Z, Goudarzi Z, Ravangard R, Shaker Z, Hedayati A, Keshavarz K. Shaker Z, et al. Cost Eff Resour Alloc. 2024 Jul 18;22(1):55. doi: 10.1186/s12962-024-00560-1. Cost Eff Resour Alloc. 2024. PMID: 39026286 Free PMC article.

170

Net costs of breast cancer in Colombia: a cost-of-illness study based on administrative claims databases.

Torres GF, Alarcón BA, Reyes-Sanchez JM, Castaño-Gamboa N, Buitrago G. Torres GF, et al. Cost Eff Resour Alloc. 2024 Jul 2;22(1):54. doi: 10.1186/s12962-024-00562-z. Cost Eff Resour Alloc. 2024. PMID: 38956674 Free PMC article.

171

Valuating the efficiency of social security and healthcare in OECD countries from a sustainable development.

Lee LW, Chiu YH, Liu FP, Lin TY, Chang TH. Lee LW, et al. Cost Eff Resour Alloc. 2024 Jun 26;22(1):53. doi: 10.1186/s12962-024-00555-y. Cost Eff Resour Alloc. 2024. PMID: 38926787 Free PMC article.

172

Correction to: Medical expenses and its determinants in female patients with urological disorder : Sewon Park.

Park S, Ji S, Lee H, Choi H, Choi M, Lee M, Jakovljevic M. Park S, et al. Cost Eff Resour Alloc. 2024 Jun 19;22(1):52. doi: 10.1186/s12962-024-00561-0. Cost Eff Resour Alloc. 2024. PMID: 38898514 Free PMC article. No abstract available.

173

Return on investment in science: twenty years of European Commission funded research in Alzheimer's dementia, breast cancer and prostate cancer.

Jakovljevic M, Deceuninck P, Pistollato F, Daskalopoulos E, Bernasconi C, Carausu F, Rosa M, Progri A, Makarieva M, Krstic K. Jakovljevic M, et al. Cost Eff Resour Alloc. 2024 Jun 16;22(1):51. doi: 10.1186/s12962-024-00540-5. Cost Eff Resour Alloc. 2024. PMID: 38880873 Free PMC article.

174

Efficiency of hospitals in COVID-19 era: a case study of an affected country.

Hamdollahzadeh A, Nabilou B, Yusefzadeh H. Hamdollahzadeh A, et al. Cost Eff Resour Alloc. 2024 Jun 11;22(1):50. doi: 10.1186/s12962-024-00549-w. Cost Eff Resour Alloc. 2024. PMID: 38863012 Free PMC article.

175

Long-term cost-utility analysis of family therapy vs. treatment as usual for young people seen after self-harm.

Bojke C, Cottrell D, Wright-Hughes A, Farrin A, Tubeuf S. Bojke C, et al. Cost Eff Resour Alloc. 2024 May 29;22(1):49. doi: 10.1186/s12962-024-00546-z. Cost Eff Resour Alloc. 2024. PMID: 38811931 Free PMC article.

176

Medical insurance, livelihood capital and public health in China.

Sheng W, Fuchong L. Sheng W, et al. Cost Eff Resour Alloc. 2024 May 28;22(1):48. doi: 10.1186/s12962-024-00554-z. Cost Eff Resour Alloc. 2024. PMID: 38807190 Free PMC article.

177

The development of day surgery in China and the effectiveness and reflection of day surgery in ophthalmology-specialized hospitals.

Haihan D, Changfei Z, Hengli L, Ning T, Lezhen Z, Hui L. Haihan D, et al. Cost Eff Resour Alloc. 2024 May 27;22(1):47. doi: 10.1186/s12962-024-00558-9. Cost Eff Resour Alloc. 2024. PMID: 38802948 Free PMC article.

178

Cost-effectiveness of differentiated care models that incorporate economic strengthening for HIV antiretroviral therapy adherence: a systematic review.

Liang A, Wilson-Barthes M, Galárraga O. Liang A, et al. Cost Eff Resour Alloc. 2024 May 24;22(1):46. doi: 10.1186/s12962-024-00557-w. Cost Eff Resour Alloc. 2024. PMID: 38790050 Free PMC article. Review.

179

Medical expenses and its determinants in female patients with urological disorder.

Park S, Ji S, Lee H, Choi H, Choi M, Lee M, Jakovljevic M. Park S, et al. Cost Eff Resour Alloc. 2024 May 24;22(1):45. doi: 10.1186/s12962-024-00556-x. Cost Eff Resour Alloc. 2024. PMID: 38790023 Free PMC article.

180

Cost-utility analysis of prenatal diagnosis of congenital cardiac diseases using deep learning.

Ginsberg GM, Drukker L, Pollak U, Brezis M. Ginsberg GM, et al. Cost Eff Resour Alloc. 2024 May 22;22(1):44. doi: 10.1186/s12962-024-00550-3. Cost Eff Resour Alloc. 2024. PMID: 38773527 Free PMC article.

181

Cost-effectiveness of TB diagnostic technologies in Ethiopia: a modelling study.

Assebe LF, Erena AK, Fikadu L, Alemu B, Baruda YS, Jiao B. Assebe LF, et al. Cost Eff Resour Alloc. 2024 May 21;22(1):43. doi: 10.1186/s12962-024-00544-1. Cost Eff Resour Alloc. 2024. PMID: 38773636 Free PMC article.

182

Hyperkalemia in chronic kidney disease patients with and without heart failure: an Italian economic modelling study.

Stawowczyk E, Ward T, Paoletti E, Senni M, de Arellano AR. Stawowczyk E, et al. Cost Eff Resour Alloc. 2024 May 21;22(1):42. doi: 10.1186/s12962-024-00547-y. Cost Eff Resour Alloc. 2024. PMID: 38769560 Free PMC article.

183

An overview of the perspectives used in health economic evaluations.

Sittimart M, Rattanavipapong W, Mirelman AJ, Hung TM, Dabak S, Downey LE, Jit M, Teerawattananon Y, Turner HC. Sittimart M, et al. Cost Eff Resour Alloc. 2024 May 14;22(1):41. doi: 10.1186/s12962-024-00552-1. Cost Eff Resour Alloc. 2024. PMID: 38741138 Free PMC article. Review.

184

Cost effectiveness and decision analysis for national airport screening options to reduce risk of COVID-19 introduction in Uganda, 2020.

Amanya G, Washington ML, Kadobera D, Richard M, Ndyabakiira A, Harris J. Amanya G, et al. Cost Eff Resour Alloc. 2024 May 12;22(1):40. doi: 10.1186/s12962-024-00548-x. Cost Eff Resour Alloc. 2024. PMID: 38735961 Free PMC article.

185

Fetoscopic laser versus amnioreduction, septostomy, and expected management for the treatment of twin-twin transfusion syndrome (TTTS): an economic evaluation analysis in Iran.

Najafpour Z, Shayanfard K, Aghighi N, Saadati N. Najafpour Z, et al. Cost Eff Resour Alloc. 2024 May 9;22(1):39. doi: 10.1186/s12962-024-00551-2. Cost Eff Resour Alloc. 2024. PMID: 38724993 Free PMC article.

186

Real-world effectiveness of a new powered stapling system with gripping surface technology on the intraoperative clinical and economic outcomes of gastrectomy for gastric cancer.

Guo H, Zheng T, Lin Y, Tang T, Zhang Z, Wang D, Zhao X, Liu Y, Tan B, Yang P, Tian Y, Li Y, Zhao Q. Guo H, et al. Cost Eff Resour Alloc. 2024 May 6;22(1):38. doi: 10.1186/s12962-024-00534-3. Cost Eff Resour Alloc. 2024. PMID: 38711056 Free PMC article.

187

A cost-benefit analysis of mass prostate cancer screening.

Farabi H, Moradi N, Ahmadzadeh A, Aghamir SMK, Mohammadi A, Rezapour A. Farabi H, et al. Cost Eff Resour Alloc. 2024 May 5;22(1):37. doi: 10.1186/s12962-024-00553-0. Cost Eff Resour Alloc. 2024. PMID: 38705990 Free PMC article.

188

The burden of health expenditure on household impoverishment in Ethiopia: a systematic review and meta-analysis.

Tsega Y, Endawkie A, Kebede SD, Kebede N, Mihiretu MM, Bekele E, Ayele K, Asmare L, Bayou FD, Arefaynie M. Tsega Y, et al. Cost Eff Resour Alloc. 2024 May 4;22(1):36. doi: 10.1186/s12962-024-00543-2. Cost Eff Resour Alloc. 2024. PMID: 38704568 Free PMC article.

189

Impact of including productivity costs in economic analyses of vaccines for C. difficile infections and infant respiratory syncytial virus, in a UK setting.

Neri M, Mewes JC, de Almeida FA, Stoychev S, Minarovic N, Charos A, Shea KM, Steuten LMG. Neri M, et al. Cost Eff Resour Alloc. 2024 Apr 30;22(1):34. doi: 10.1186/s12962-024-00533-4. Cost Eff Resour Alloc. 2024. PMID: 38689331 Free PMC article.

190

Rapid cost-effectiveness analysis: hemodialysis versus peritoneal dialysis for patients with acute kidney injury in Rwanda.

Nemzoff C, Ahmed N, Olufiranye T, Igiraneza G, Kalisa I, Chadha S, Hakiba S, Rulisa A, Riro M, Chalkidou K, Ruiz F. Nemzoff C, et al. Cost Eff Resour Alloc. 2024 Apr 30;22(1):35. doi: 10.1186/s12962-024-00545-0. Cost Eff Resour Alloc. 2024. PMID: 38689271 Free PMC article.

191

Economic evaluations of medical devices in paediatrics: a systematic review and a quality appraisal of the literature.

Mascarenhas E, Miguel LS, Oliveira MD, Fernandes RM. Mascarenhas E, et al. Cost Eff Resour Alloc. 2024 Apr 27;22(1):33. doi: 10.1186/s12962-024-00537-0. Cost Eff Resour Alloc. 2024. PMID: 38678250 Free PMC article. Review.

192

Cost-effectiveness of sacituzumab govitecan versus single-agent chemotherapy for metastatic triple-negative breast cancer: a trial-based analysis.

Wu Y, Hu S, Liu X, Chen Y, Luan J, Wang S. Wu Y, et al. Cost Eff Resour Alloc. 2024 Apr 24;22(1):32. doi: 10.1186/s12962-024-00539-y. Cost Eff Resour Alloc. 2024. PMID: 38659013 Free PMC article.

193

Nursing labor supply in Iran: a survey in Shiraz public hospitals in 2022.

Keshavarzi A, Delavari S, Lotfi F, Goudarzi Z, Bashiri F, Bayati M. Keshavarzi A, et al. Cost Eff Resour Alloc. 2024 Apr 22;22(1):31. doi: 10.1186/s12962-024-00542-3. Cost Eff Resour Alloc. 2024. PMID: 38650021 Free PMC article.

194

The value of admission avoidance: cost-consequence analysis of one-year activity in a consolidated service.

Hernandez C, Herranz C, Baltaxe E, Seijas N, González-Colom R, Asenjo M, Coloma E, Fernandez J, Vela E, Carot-Sans G, Cano I, Roca J, Nicolas D. Hernandez C, et al. Cost Eff Resour Alloc. 2024 Apr 15;22(1):30. doi: 10.1186/s12962-024-00536-1. Cost Eff Resour Alloc. 2024. PMID: 38622593 Free PMC article.

195

Health economic evaluation of blended collaborative care for older multimorbid heart failure patients: study protocol.

Derendorf L, Stock S, Simic D, Shukri A, Zelenak C, Nagel J, Friede T, Herbeck Belnap B, Herrmann-Lingen C, Pedersen SS, Sørensen J, Müller And On Behalf Of The Escape Consortium D. Derendorf L, et al. Cost Eff Resour Alloc. 2024 Apr 13;22(1):29. doi: 10.1186/s12962-024-00535-2. Cost Eff Resour Alloc. 2024. PMID: 38615050 Free PMC article.

196

Comparison of current relative value unit-based prices and utility between common surgical procedures, including orthopedic surgeries, in South Korea.

Choi YH, Kwon TH, Chung CY, Jeong N, Lee KM. Choi YH, et al. Cost Eff Resour Alloc. 2024 Apr 11;22(1):27. doi: 10.1186/s12962-024-00538-z. Cost Eff Resour Alloc. 2024. PMID: 38605377 Free PMC article.

197

Modelled cost-effectiveness analysis of the Support and Treatment After Replacement (STAR) care pathway for chronic pain after total knee replacement compared with usual care.

Cole S, Noble S, Gooberman-Hill R, Pinedo-Villanueva R. Cole S, et al. Cost Eff Resour Alloc. 2024 Apr 11;22(1):28. doi: 10.1186/s12962-024-00532-5. Cost Eff Resour Alloc. 2024. PMID: 38605347 Free PMC article.

198

The cost-effectiveness of school-based interventions for chronic diseases: a systematic review.

Lin G, Werner K, Alqunaiebet A, Hamza MM, Alkanhal N, Alsukait RF, Alruwaily A, Rakic S, Cetinkaya V, Herbst CH, Lin TK. Lin G, et al. Cost Eff Resour Alloc. 2024 Apr 11;22(1):26. doi: 10.1186/s12962-024-00511-w. Cost Eff Resour Alloc. 2024. PMID: 38605333 Free PMC article. Review.

199

The economic burden of hemodialysis and associated factors of among patients in private and public health facilities: a cross-sectional study in Addis Ababa, Ethiopia.

Baye TA, Gebeyehu H, Bekele M, Abdelmenan S, Ashengo TA, Mengistu B. Baye TA, et al. Cost Eff Resour Alloc. 2024 Apr 4;22(1):25. doi: 10.1186/s12962-024-00530-7. Cost Eff Resour Alloc. 2024. PMID: 38575968 Free PMC article.

200

Cost-utility analysis of TAVI compared with surgery in patients with severe aortic stenosis at low risk of surgical mortality in the Netherlands.

Eerdekens R, Kats S, Grutters JP, Green M, Shore J, Candolfi P, Oortwijn W, Harst PV, Tonino P. Eerdekens R, et al. Cost Eff Resour Alloc. 2024 Mar 26;22(1):24. doi: 10.1186/s12962-024-00531-6. Cost Eff Resour Alloc. 2024. PMID: 38528520 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Results by year

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

892 results

Results by year

Search Page

Filters

My Custom Filters

Results by year

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

892 results

Results by year